Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

AbbVie

Inovio Pharmaceuticals

Pfizer

Sanofi

Could these top biotech stocks be worth investing in for the long term?

5 Biotech Stocks To Check Out In The Stock Market Now

Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine.

Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU

Amazon

Teladoc

The way 2022 is shaping up off and on the price charts, investors may consider these three Covid stocks to buy for a healthier portfolio. The post 3 Second-Shot Covid Stocks to Buy appeared first on InvestorPlace.

3 Second-Shot Covid Stocks to Buy

LOS ANGELES--(BUSINESS WIRE)---- $NVAX #NVAX--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a federal securities class action lawsuit has been filed against Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) in the United States District Court for the District of Maryland on behalf of those who purchased Novavax common stock between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). All investors who purchased shares of  Novavax, Inc. a nd incurred losses are u rged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

NOVAVAX, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against Novavax, Inc.

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by 7.92% yesterday. This is why it happened.

Novavax (NVAX) Stock: Why The Price Jumped

Novavax is finally healing after months of being beaten down. Is this the start of a big rally or a fragile recovery for NVAX stock?

Novavax Stock Looks To Be In Recovery Mode

Investors have been waiting months for this moment.

Should You Buy Novavax Before Its U.S. Regulatory Filing?

Lightspeed Commerce Inc

Zillow

NEW YORK, NY / ACCESSWIRE / November 18, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: Z LSPD NVAX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, Nov. 17, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Novavax, Inc. ("Novavax") (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the District of Maryland and alleges violations of the Securities Exchange Act of 1934.

NOVAVAX, INC. (NASDAQ: NVAX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Novavax, Inc.

Radnor, Pennsylvania--(Newsfile Corp. - November 17, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed United States District of Court for the District of Maryland against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's...

Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Novavax, Inc.

Boston, Massachusetts--(Newsfile Corp. - November 17, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

NOVAVAX INVESTOR ALERT: Shareholder Lawsuit Filed

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). Novavax investors have until January 11, 2022 to file a lead plaintiff motion. If you suffered a loss on your Novavax inves

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Novavax, Inc. (NVAX) Investors

The European Medicines Agency (EMA) has begun evaluating an application for conditional marketing authorization for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine. The protein-based vaccine candidate will be marketed in the European Union under the brand name Nuvaxovid.

Novavax Shares Are Rising On Incremental COVID-19 Vaccine Related News

Today, shares of NVAX stock are taking off following a couple of key regulatory updates from the company from two core markets. The post NVAX Stock Alert: 2 Big Reasons Novavax Shares Are Climbing Today appeared first on InvestorPlace.

NVAX Stock Alert: 2 Big Reasons Novavax Shares Are Climbing Today

The European Medicines Agency said it could make a decision on the shot “within weeks.”

European Regulator Starts Assessing Novavax's Covid Vaccine—Stock Jumps 8%

SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now.  Class Period: Mar. 2, 2021 – Oct. 19, 2021 Lead Plaintiff Deadline: Jan. 11, 2022 Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: NVAX@hbsslaw.com                                              844-916-0895 Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax's progress toward successfully developing its COVID-19 vaccine (NVX-CoV2373), including: (1) overstating Novavax's manufacturing capabilities and downplaying manufacturing issues that would impact the approval timeline for NVX-CoV2373; (2) concealing that Novavax was unlikely to meet its anticipated EUA regulatory timelines; (3) exaggerating the regulatory and commercial prospects for NVX-CoV2373.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Novavax (NVAX) Investors with Significant Losses to Contact Firm's Attorneys Now, Securities Class Action Filed

GAITHERSBURG, Md., Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax' COVID-19 vaccine, which will be marketed in the European Union under the brand name Nuvaxovid™.

Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization

Novavax may soon get authorisation from several countries and this will take the revenue to record high. NVAX stock is a long term buy.

Novavax Stock Is a Long-Term Investment in an Extended Pandemic

Novavax Inc. NVAX, -1.14% and Serum Institute of India said Wednesday that the Philippine Food and Drug Administration has granted emergency use authorization to Novavax' COVID-19 vaccine with Matrix-M(TM) adjuvant. The vaccine will be made in the Philippines by the SII under the brand name Covovax.

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

GAITHERSBURG, Md. and PUNE, India, Nov. 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased acquired Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). Novavax investors have until January 11, 2022 to file a lead plaintiff motion. Investors suffering losses on their Novavax investments are encouraged to contact the Law Offices of Howard G. Sm

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Novavax, Inc. (NVAX) Investors

SAN DIEGO--(BUSINESS WIRE)-- #NVAXstock--The suit alleges defendants issued false statements concerning Novavax business and prospects, resulting in its stock trading at inflated prices.

DEADLINE: Novavax, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NVAX

SAN DIEGO--(BUSINESS WIRE)---- $NVAX #COVID19--Novavax, Inc. (NVAX) Misled Shareholders Regarding Approval of its COVID Vaccine

SHAREHOLDER ALERT: Robbins LLP Informs Investors of Class Action Against Novavax, Inc. (NVAX)

Los Angeles, California--(Newsfile Corp. - November 16, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novavax is the subject of an article published by Politico on October...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novavax, Inc. and Encourages Investors with Losses to Contact the Firm

News for Novavax Stock (NVAX)